Amylyx Pharmaceuticals (AMLX) Net Income towards Common Stockholders (2021 - 2026)

Amylyx Pharmaceuticals' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$91.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 153.29% year-over-year to -$91.0 million; the TTM figure through Mar 2026 stood at -$199.8 million (down 28.23% YoY), while the FY2025 annual figure was -$144.7 million, up 39.36% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$91.0 million, down from -$33.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $25.5 million in Q4 2024, with the low at -$118.8 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is -$41.4 million (2025), against an average of -$36.9 million.
• Peak annual rise in Net Income towards Common Stockholders reached 845.87% in 2024, while the deepest fall reached 7652.0% in 2024.
• Amylyx Pharmaceuticals' Net Income towards Common Stockholders stood at -$43.8 million in 2022, then jumped by 106.16% to $2.7 million in 2023, then jumped by 845.87% to $25.5 million in 2024, then sank by 229.36% to -$33.0 million in 2025, then sank by 175.61% to -$91.0 million in 2026.
• Business Quant data shows AMLX's Net Income towards Common Stockholders at -$91.0 million in Q1 2026, -$33.0 million in Q4 2025, and -$34.4 million in Q3 2025.